Trial Profile

A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KB 001-A (Primary)
Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
Focus Adverse reactions
Sponsors Humanigen

Most Recent Events

07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
18 May 2010 Results reported at American Thoracic Society meeting according to a KaloBios media release.
16 Oct 2009 Results have been reported at the North American Cystic Fibrosis Conference, according to a KaloBios Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com